Loading [MathJax]/jax/output/SVG/jax.js
Review

The impact of p38 MAPK, 5-HT/DA/E signaling pathways in the development and progression of cardiovascular diseases and heart failure in type 1 diabetes

  • Received: 07 August 2020 Accepted: 20 October 2020 Published: 23 October 2020
  • Serotonin or 5-HT, DA and E, all monoamine neurotransmitters, work also as hormones, plays crucial role in the brain and body. This 5-HT, DA and E increased significantly, and regulated by activated p38 MAPK in type I diabetes mellitus (T1DM), and that has been shown to involve in metabolic disorders as well as cardiovascular diseases, leading to heart failure. Even though these molecules are being considered for clinical trials in the treatments of various cardiovascular diseases, the synergistic-pathophysiological mechanisms of these p38 MAPK and neurotransmitters on target molecules, cells and tissues in heart failure are not completely understood in T1DM. However, T1DM results in metabolic dysregulation, impairment/loss of insulin secretion, hyperglycemia and acidosis. These changes are widely reported to be involved in abnormal functions of receptors, which provide binding site for signaling molecules. We are constantly focusing on the mechanisms of alloxan-induced-diabetes, glucose-induced-hyperglycemia and ammonium chloride-induced-acidosis (non-diabetic hyperglycemia (NDH) and non-diabetic acidosis (NDA), respectively) on the levels and functions of neurotransmitters and p38 MAPK. Here, in this review, we are proposing the mechanisms of insulin and/or some of the pharmacological agents on the level and functions of p38 MAPK and neurotransmitters in various areas of rat brain under diabetic or its associated conditions, which leads to cardiovascular dysfunctions. Targeting these molecules/pathways may be useful in the treatment of cardiovascular diseases and diabetes mediated heart failure.

    Citation: Ramakrishnan Ramugounder. The impact of p38 MAPK, 5-HT/DA/E signaling pathways in the development and progression of cardiovascular diseases and heart failure in type 1 diabetes[J]. AIMS Molecular Science, 2020, 7(4): 349-373. doi: 10.3934/molsci.2020017

    Related Papers:

    [1] Sameh Halaoua, Sonia Boukattaya . Does gender diversity in the audit committee influence corporate dividend policy? Evidence from French listed firms. Green Finance, 2023, 5(3): 373-391. doi: 10.3934/GF.2023015
    [2] Muhammad Junaid, Ye Xue, Muzzammil Wasim Syed, Muhammad Ziaullah, Numair Riffat . Corporate governance mechanism and performance of insurers in Pakistan. Green Finance, 2020, 2(3): 243-262. doi: 10.3934/GF.2020014
    [3] Óscar Suárez-Fernández, José Manuel Maside-Sanfiz, Mª Celia López-Penabad, Mohammad Omar Alzghoul . Do diversity & inclusion of human capital affect ecoefficiency? Evidence for the energy sector. Green Finance, 2024, 6(3): 430-456. doi: 10.3934/GF.2024017
    [4] Mohamad Nur Utomo, Sri Rahayu, Kaujan Kaujan, Soni Agus Irwandi . Environmental performance, environmental disclosure, and firm value: empirical study of non-financial companies at Indonesia Stock Exchange. Green Finance, 2020, 2(1): 100-113. doi: 10.3934/GF.2020006
    [5] Fu-Hsaun Chen . Green finance and gender equality: Keys to achieving sustainable development. Green Finance, 2024, 6(4): 585-611. doi: 10.3934/GF.2024022
    [6] Joseph F. Hair, Juan José García-Machado, Minerva Martínez-Avila . The impact of organizational compliance culture and green culture on environmental behavior: The moderating effect of environmental commitment. Green Finance, 2023, 5(4): 624-657. doi: 10.3934/GF.2023024
    [7] Sabuj Saha, Ahmed Rizvan Hasan, Kazi Rezwanul Islam, Md Asraful Islam Priom . Sustainable Development Goals (SDGs) practices and firms' financial performance: Moderating role of country governance. Green Finance, 2024, 6(1): 162-198. doi: 10.3934/GF.2024007
    [8] Leo-Paul DANA, Mohammad Mahdi Rounaghi, Gholamreza Enayati . Increasing productivity and sustainability of corporate performance by using management control systems and intellectual capital accounting approach. Green Finance, 2021, 3(1): 1-14. doi: 10.3934/GF.2021001
    [9] Tõnis Mets, Piia Vettik-Leemet . Women in the sustainability new ventures in the digital era: Out from the shadow of the small country male-dominated startup ecosystem. Green Finance, 2024, 6(3): 383-406. doi: 10.3934/GF.2024015
    [10] Rizwan Ullah Khan, Hina Arif, Noor E Sahar, Arif Ali, Munir A. Abbasi . The role of financial resources in SMEs' financial and environmental performance; the mediating role of green innovation. Green Finance, 2022, 4(1): 36-53. doi: 10.3934/GF.2022002
  • Serotonin or 5-HT, DA and E, all monoamine neurotransmitters, work also as hormones, plays crucial role in the brain and body. This 5-HT, DA and E increased significantly, and regulated by activated p38 MAPK in type I diabetes mellitus (T1DM), and that has been shown to involve in metabolic disorders as well as cardiovascular diseases, leading to heart failure. Even though these molecules are being considered for clinical trials in the treatments of various cardiovascular diseases, the synergistic-pathophysiological mechanisms of these p38 MAPK and neurotransmitters on target molecules, cells and tissues in heart failure are not completely understood in T1DM. However, T1DM results in metabolic dysregulation, impairment/loss of insulin secretion, hyperglycemia and acidosis. These changes are widely reported to be involved in abnormal functions of receptors, which provide binding site for signaling molecules. We are constantly focusing on the mechanisms of alloxan-induced-diabetes, glucose-induced-hyperglycemia and ammonium chloride-induced-acidosis (non-diabetic hyperglycemia (NDH) and non-diabetic acidosis (NDA), respectively) on the levels and functions of neurotransmitters and p38 MAPK. Here, in this review, we are proposing the mechanisms of insulin and/or some of the pharmacological agents on the level and functions of p38 MAPK and neurotransmitters in various areas of rat brain under diabetic or its associated conditions, which leads to cardiovascular dysfunctions. Targeting these molecules/pathways may be useful in the treatment of cardiovascular diseases and diabetes mediated heart failure.


    The presence of women on boards of directors has increased significantly in recent years (Spencer Stuart, 2022), boosting corporate and academic interest in understanding the impact of their presence on corporate performance (Laique et al., 2023; Mumu et al., 2022; Baker et al., 2020). Parallel to social and academic interest in the role of women in positions of responsibility in firms, another key challenge has emerged, namely what environmental impact firms have. According to the report Reaching Net Zero by 2050, based on an analysis of over 1,000 listed companies in main European stock market indices, firms' commitment to reach zero greenhouse gas emissions has accelerated over the last two years. Also, almost a third of the largest European listed companies have set themselves the target of achieving this reduction by 2050 (Bouckaert et al., 2021). This commitment has been driven by increased pressure from both investors and consumers, who demand more environmentally responsible behaviors from firms and governments (Al Amosh, 2024a; Liu, 2018; Ioannou & Serafeim, 2015; Flammer, 2013). The increasing stakeholder demand for sustainable practices has strengthened firms' environmental commitment, leading them to adopt standards that are more beneficial for the planet in the long term. A new strand of literature has thus emerged focusing on investigating firms' environmental performance, highlighting the importance of sustainable practices and their positive impact on the environment (Ananzeh et al., 2024; Liao and Zhang, 2024; Al Amosh & Khatib, 2023; Nadeem, 2021; Henry et al., 2019; Liu, 2018; Bhandari and Javakhadze, 2017; Fernando et al., 2017; Ferrell et al., 2016; Flammer, 2015; Krüger, 2015), and pointing to the importance of board composition in determining firms' social performance (Al Amosh, 2024b; Esterhuyse, 2020; Kikwiye, 2019).

    In this setting, some examples point to female leadership as being key to promoting sustainable practices in global firms. Mary Barra, CEO of General Motors, has led the transition to electric vehicles and has committed to achieving net zero emissions by 2040. Isabelle Kocher, former CEO of Engie in France, has driven a transition to cleaner energy, focusing on energy efficiency and investment in renewable energy. Ana Botín, president of Banco Santander, has integrated environmental, social, and governance (ESG) criteria into the bank's strategy, promoting sustainability and moving toward a green economy. Lisa Jackson, the vice president of Apple, has been instrumental in implementing a model based on the exclusive use of renewable energy in the firm's operations. In addition, academic literature has highlighted the presence of female directors as a key factor in firms' ethical performance (Kamran et al., 2023; Wu et al., 2022; Amorrelli & García-Sánchez, 2020; Liao et al., 2015; Post et al., 2011). However, firms can be both socially "good and bad" at the same time (Fleitas-Castillo et al., 2024; Clark et al., 2022; Nardella et al., 2020; Keig et al., 2015; Herzig & Moon, 2013; Strike et al., 2006). Analysis of firms' social behavior therefore proves complex and requires a holistic approach to assess the true social impact of corporate activities. While firms may be increasing their environmental responsibility through more responsible and environmentally friendly practices, they may also, at the same time, be engaging in irresponsible actions that harm the environment. Exploring the drivers of unethical corporate behavior thus emerges as a pivotal issue. Previous literature points to the pressure to reduce costs, the lack of strict regulations, or the weakness of institutions as drivers of irresponsible actions (Gao & Yang, 2021; Surroca et al., 2013; Boudier & Bensebaa, 2011; Matten & Moon, 2008; Matten & Moon, 2005). Nevertheless, the relationship between female directors and episodes of environmental irresponsibility in firms has been largely overlooked.

    The relationship between gender diversity and environmental violations remains unclear from a theoretical standpoint, and female directors may be key contributors to higher ethical standards, greater scrutiny, and high-quality decision-making, stemming from a variety of experiences and perspectives (Feng & Xiang, 2023; Briano-Turrent, 2022; Ongsakul et al., 2021; Adams et al., 2015; Gul et al., 2011; Adams & Ferreira, 2009; Cox & Blake, 1991). These studies suggest that female directors exhibit greater independence from the "old boys' club" and show more concern for their reputational role in overseeing corporate decisions (Kamil & Appiah, 2022; Nadeem et al., 2020; Levi et al., 2014). Compared to male directors, female directors tend to better safeguard stakeholder concerns by avoiding opportunistic performance (Javeed et al., 2022; Usman et al., 2019; Zalata et al., 2019). In addition, they enhance the firm's legitimacy by increasing trust, transparency, and ethical reputation, thus attracting investors, customers, and employees (Zahid et al., 2025; Nadeem, 2021). However, from an attribution perspective, the appointment of female directors might be used as a symbolic strategy to mitigate any negative impact on the setting, i.e., the firm might use female directors as an instrument to increase stakeholder trust so that stakeholders react less negatively to unethical performance (Nirino et al., 2021). Female directors therefore act as moral capital or as an "insurance policy" that protects the firm from the negative effects of environmental violations, giving it "the benefit of the doubt" regarding the organization's intentions (Godfrey, 2005; Klein & Dawar, 2004; Borghesi et al., 2014; Shiu & Yang, 2017). In addition, the presence of female directors might create fault lines in the board by dividing it into subgroups based on directors' demographic characteristics (Mäs et al., 2013; Lau & Murnighan, 1998). The presence of fault lines leads to weaker board performance (Thatcher et al., 2003), which may facilitate the occurrence of environmental violations.

    We aim to shed light on this issue by examining the impact of female directors on corporate environmental violations. To achieve this, we analyzed a sample of European non-financial firms included in the Euro Stoxx 600 from 2016 to 2022. Drawing on information provided by the Good Jobs First database, we used environmental fines as a measure of corporate environmental misconduct. These fines represent substantiated violations of environmental regulations and are imposed by government agencies as a result of official investigations, thereby providing a clear and transparent resolution of environmental infractions (Duan et al., 2024; Foulon & Marsat, 2023; Raghunandan & Rajgopal, 2022; Wu et al., 2021; Wang et al., 2020; Du, 2015). Furthermore, due to their more direct nature and the authority of the regulatory actions that lie behind them, environmental fines are not susceptible to corporate manipulation through greenwashing—a tactic used by some firms to improve their public image without adequately addressing environmental concerns (Birindelli et al., 2024; Eliwa et al., 2023; Liu, 2018; Matejek & Gössling, 2014; Laufer, 2003; Fields, 2002). We employed various models to address endogeneity and data-censoring problems. In all cases, results showed a negative impact of the presence of female directors on firms' environmental sanctions.

    Our study makes several contributions to existing literature. First, it enhances the current understanding of what impact women in leadership roles have on corporate policies, particularly those affecting the environment. This highlights the outcomes and implications of policies that promote gender diversity in the corporate arena (García-Meca et al., 2022; Liu et al., 2014; Cumming et al., 2015; Adams & Ferreira, 2009). While previous research has found a link between gender diversity and increased positive corporate social responsibility initiatives (Javeed et al., 2022; Orazalin & Baydauletov, 2020; McGuinness et al., 2017), the influence of female directors on corporate environmental misbehavior remains largely unexplored. This study addresses this gap by using environmental sanctions as a direct measure of environmental misconduct, providing new evidence that greater gender representation in firms is associated with fewer environmental violations. Second, this research contributes to the literature on environmental risks and corporate governance (Kazim et al., 2024; Shahab et al., 2023; Abebe & Acharya, 2022; Carvajal et al., 2022; Kyaw et al., 2022; Kassinis & Vafeas, 2002) providing further evidence to the study of Liu (2018) by showing that gender diversity on boards correlates with a reduction in environmental violations in a setting of low litigation risk, a high prevalence of ownership concentration (Djankov et al., 2008; La Porta et al., 1999), and where reputation plays a prominent role as a mechanism to discipline dominant owners and managers (Young et al., 2008; Cuervo, 2002; La Porta et al., 1998, 2000). Additionally, we employ a multi-theoretical approach that incorporates theories such as agency, legitimacy, upper echelons, resource dependence, human capital, attribution, and fault lines. The study also provides empirical support for the idea that greater female representation in corporate governance might reduce environmental violations by firms. Finally, the study helps to evaluate environmental violations by using fines as a measure of firms' environmental irresponsibility (Duan et al., 2024; Foulon & Marsat, 2023; Raghunandan & Rajgopal, 2022; Wu et al., 2021; Wang et al., 2020; Du, 2015). Penalties represent the best proxy for measuring environmental irresponsibility because they directly reflect the sanctions imposed by regulators that result from specific breaches of environmental regulations.

    The relationship between board gender diversity and environmental violations might vary significantly between regions due to cultural, regulatory, and economic factors. Europe leads the way in female representation thanks to the push for more advanced policies such as gender quotas and greater commitment to environmental protection and sustainability, as well as greater regulatory and social pressure to comply with ESG standards (Wang et al., 2021), which contrasts with Asia and emerging economies. In Asia, cultural traditions persist and there is still a more centralized corporate governance system, which tends to limit the impact of female directors on sustainability strategies. Cultural traditions deeply rooted in Confucianism thus perpetuate traditional views of the role of women in the family and restrict their career advancement (He, 2023; Taylor, 2005). Additionally, the historical context of market liberalization in China, which commenced in 2005, has further reinforced these gender barriers, since this more liberal economic model significantly reduced state intervention in feminist policies, favoring a male-dominated work setting and limiting opportunities for female advancement (Bell, 2010; Jiang, 2009). These gender barriers are most evident in key industries in the country, many of which have a high environmental impact and are dominated by traditional power structures (Yao et al., 2020). Accordingly, despite great economic progress in the socio-political context, culture continues to profoundly influence the role of women in Chinese firms. This is illustrated by the Deloitte report (2024), which shows that only 15.1% of board seats in China are held by women, a considerably lower percentage than the European average of approximately 30%. In this context, environmental violations in China are subject to severe government sanctions that increase financial costs for the firms responsible (Ma et al., 2022; Du et al., 2017). Limited female representation on boards thus hinders the implementation of more environmentally responsible policies, given the lower weight of diverse perspectives in strategic decision-making (Iwasaki et al., 2024).

    Emerging economies such as Pakistan, Malaysia, and Thailand are characterized by concentrated ownership structures, especially in family-owned firms, where owners exercise significant control over strategic decisions (Carney & Child, 2013; Wei & Zhang, 2008; Du & Dai, 2005; Claessens et al., 2000). Although the presence of women on boards may improve practices related to sustainability and the environment, their effect on environmental violations is limited due to cultural barriers and the difficulty involved in accessing influential leadership positions (Yasser et al., 2017). In addition, environmental regulations in these regions tend to be weaker and enforcement less strict, which reduces incentives to adopt policies that prioritize sustainability (Amin et al., 2023). Consequently, Europe becomes a setting of particular concern for analyzing the gender diversity–environmental violations relationship due to the significant presence of female directors and the importance of environmental actions for stakeholders, such that the results obtained may help to establish policy strategies in other settings.

    Environmental sustainability has become a crucial factor for firms due to growing investor sensitivity toward the environment and less tolerance toward practices that damage the natural environment (Birindelli et al., 2024; Eliwa et al., 2023; Bolton & Kacperczyk, 2021). In this regard, Krueger et al. (2020) showed that climate risks are a major concern for institutional investors and have a significant impact on the valuation of firms with poor environmental practices. Flammer (2021) added that firms who engage in green finance, such as issuing green bonds, experience positive valuation effects, in contrast to the negative impacts observed for firms who engage in harmful environmental practices. Cheng et al. (2023) and Flamer (2013) also pointed out that increased investor awareness of environmental issues has led to harsher penalization of firms that damage the environment. Ioannou & Serafeim (2015) concluded that the relationship between ESG criteria and financial performance has strengthened, especially as stakeholders become less tolerant of negative impacts on the environment (Eliwa et al., 2023). Taken together, these studies underline the growing importance of environmental sustainability for firms, not only for ethical and social responsibility reasons but also because of the direct impact on valuation and financial performance.

    However, firms may commit acts against the environment mainly due to pressure to maximize short-term profits and to cut operating costs (Atay & Terpstra-Tong, 2020; Boudier & Bensebaa, 2011; Campbell, 2007), which leads them to minimize environmental management costs and to opt for more economical—albeit environmentally damaging—practices (Chen & Dagestani, 2023; Yu et al., 2020; Delmas & Toffel, 2008). According to Delmas & Pekovic (2013), adopting innovative environmental practices can be hampered by the perception of high costs and risks, leading firms to prioritize immediate benefits over long-term sustainability. In addition, the lack of strong sanctions or the weak enforcement of environmental regulations in certain regions may incentivize firms to take risks and commit environmentally irresponsible acts (Xia et al., 2023; Zou et al., 2015; Darnall et al., 2008). Managers and dominant owners may therefore have the incentive to engage in environmentally irresponsible acts. Executive compensation is often linked to short-term financial metrics such as share price and quarterly earnings, which may encourage decisions that provide immediate results at the expense of environmental sustainability (Eccles et al., 2014). In addition, dominant owners—especially in family-owned or investment group-controlled firms—may push to maximize short-term profitability and ignore long-term environmental risks (Fleitas-Castillo et al., 2024; Berrone et al., 2012). In some cases, the lack of a corporate culture focused on social and environmental responsibility may result in decision-making that neglects the ecological impact (García-Sánchez et al., 2016).

    In this context, one effective strategy is to incorporate women into boards of directors, as numerous studies have indicated that female presence in management roles can foster more responsible and sustainable corporate behavior (Kamran et al., 2023; Wu et al., 2022; Amorrelli & García-Sánchez, 2020; Liao et al., 2015; Post et al., 2011). This aligns with the argument that women display greater awareness and pragmatism when it comes to environmental issues, whereas men often exhibit more skepticism and focus on the financial aspects of green initiatives (Lu & Herremans, 2019). Furthermore, women generally show more concern for environmental issues and are more generous and humanitarian, as well as more attuned to stakeholder demands (Oyewo, 2023; Saeed et al., 2022; Kassinis et al., 2016). According to García-Sánchez et al. (2023), female leadership is positively linked with achieving the 2030 Agenda goals related to environmental protection and promoting sustainable practices. Incorporating female directors not only helps to mitigate environmental risks but also enhances the firm's reputation, making it more attractive to investors who increasingly value a commitment to responsible and sustainable practices.

    Nevertheless, the appointment of female directors might be used as a symbolic strategy that incentivizes environmental violations, with women being employed as an instrument that benefits the firm's public image (Nirino et al., 2021). Furthermore, the presence of female directors might create fault lines on the board (Lau & Murnighan, 1998; Mäs et al., 2013), generating subgroups that undermine the board's work (Thatcher et al., 2003) and lead to unethical environmental performance. The effect of board gender diversity on environmentally damaging actions is therefore a complex issue from a theoretical perspective.

    Different theoretical arguments support a negative relationship between the presence of female directors and the performance of environmental practices. From an agency perspective, the presence of women improves oversight and control over managers and dominant owners (Kamil & Appiah, 2022; Nadeem et al., 2020; Levi et al., 2014) and reduces opportunistic and irresponsible performance (Javeed et al., 2022; Usman et al., 2019; Zalata et al., 2019). In addition, women tend to take into account a wider range of concerns and values in decision-making, which reduces the possibility of engaging in environmentally harmful performance (Javeed et al., 2022). As such, the presence of female directors increases their visibility, enhancing their incentives to signal their control over the firm's performance. This is due to the fact that the female labor market is narrower than that of their male counterparts, which implies facing higher reputational costs that may condition possible future appointments (Fleitas-Castillo et al., 2024; Godfrey et al., 2024; Gilson, 1990). Similarly, the upper echelon theory justifies the reduction of environmental malpractices as a consequence of greater female representation on the board (Perryman et al., 2016; Graham et al., 2017), as it facilitates the influence on corporate decision-making of the characteristics associated with female directors, such as higher ethical performance, control, and concern for stakeholders' demands.

    The resource dependence theory argues that organizations depend on external resources for their survival and success (Tejersen et al., 2009; Pfeffer and Salancik, 1978). Accordingly, female appointments to boards might enhance firms' ability to access a wide range of resources, such as knowledge, perspectives, contacts, reputation, and information (Martinez-Garcia et al., 2022; Nguyen et al., 2015; Ali et al., 2014). This is especially relevant in the environmental context, where the firm may need access to natural or technological resources to implement sustainable practices. In addition, women tend to show greater concern for the environment, while men tend to be more concerned with financial aspects than with green initiatives (Lu and Herremans, 2019). Female directors can provide the firm with different perspectives and networks that facilitate access to critical resources, and they may also enhance the firm's reputation and credibility as well as attract more resources and investment opportunities (Nadeem, 2020; Krishnan & Park, 2005). Strengthening the firm's resource base reduces the need to resort to irresponsible practices to obtain resources, which has been identified as one of the main reasons why firms engage in unethical performance (Gao & Yang, 2021; Boudier & Bensebaa, 2011). Complementary arguments—such as human capital theory—posit that firms benefit significantly from having directors who possess a diversity of skills and knowledge (Zhu et al., 2024; Terjesen et al., 2009). Female directors improve regulatory compliance (Gull et al., 2018; Rao & Tilt, 2016) since the effectiveness of oversight and resource allocation functions is enhanced by the board's greater knowledge and skills (Maswadi & Amran, 2023). In the environmental context, such board diversity can enhance the firm's ability to effectively identify and address environmental challenges (Hafsi & Turgut, 2013), thereby enriching decision-making and discouraging environmental breaches, as the inclusion of women on the board promotes sustainable practices (Zhu et al., 2024). Additionally, the presence of female directors favors the arguments provided by the gender socialization theory, according to which greater diversity increases the board's pool of experience, knowledge, and skills, thus reducing environmental malpractices (Zahid et al., 2025).

    For its part, legitimacy theory suggests that firms must maintain legitimacy and social acceptance in order to survive and prosper in the long term (Suchman, 1995). This implies that they must align their practices and objectives with the expectations and norms of the society in which they operate, thereby ensuring their long-term sustainability and success (Giannarakis et al., 2023). The inclusion of female directors on the board can enhance the public perception and legitimacy of the firm and demonstrate a commitment to gender diversity and corporate responsibility. Furthermore, previous literature indicates that the presence of female directors is related to greater ethics (Nadeem, 2021), greater stakeholder interest (Javeed et al., 2022), improved accountability (Lucas-Perez et al., 2015), greater transparency (Ain et al., 2021), and to promoting a culture of responsibility and ethics. A firm that is perceived as being ethical and responsible is more likely to be seen as legitimate and worthy of stakeholder support (Nadeem, 2021). In addition, women directors—who have greater difficulty accessing these positions and who face a narrower labor market—must be particularly careful with their reputational capital (Godfrey et al., 2024), which leads them to advocate for avoiding environmentally damaging actions (Giannarakis et al., 2023; Oyewo, 2023; Shakil et al., 2021; Arayssi et al., 2020; Nadeem et al., 2020).

    The presence of female directors may, nevertheless, encourage harmful environmental practices, and their appointment may have a merely symbolic role or impair the effectiveness of the board. From an attribution perspective, female directors can be used as instruments to mitigate any negative impact on the firm when environmental violations are uncovered. Consequently, female directors can be a mechanism to increase stakeholder confidence such that the latter react less negatively to unethical performance (Nirino et al., 2021). As a result, female directors act as moral capital and as an insurance policy to protect the firm from the negative effects of environmental violations by giving the company "the benefit of the doubt" regarding its true intentions (Shiu and Yang, 2017; Borghesi et al., 2014; Godfrey, 2005; Klein and Dawar, 2004).

    Board gender diversity may also be a factor that encourages poor environmental practices due to the presence of fault lines on the board, i.e., hypothetical lines that divide the board into subgroups based on their demographic characteristics (Mäs et al., 2013; Lau & Murnighan, 1998). The presence of fault lines leads to poorer board performance and less communication among board members (Thatcher et al., 2003). Any fault lines that could arise between different subgroups in a diverse board may therefore separate and complicate cohesion and communication due to categorization, stereotypes, and biases (Arena et al., 2024; Leicht-Deobald et al., 2021; Wu et al., 2021; Crucke & Knockaert, 2016; Carton & Cummings, 2012). In this setting, conflicts emerge between subgroups and can polarize opinions and reduce coordination, information sharing, and idea creation (Sun et al., 2023; Pearsall et al., 2008). This can lead to divergent views on firms' social performance (Ma & Huang, 2023; Ludwig & Sassen, 2022; Endrikat et al., 2021; Byron & Post, 2016) and diminish the board's ability to respond to stakeholder demands (Vandebeek et al., 2021; Donaldson et al., 2020). Accordingly, we state the following hypothesis:

    H: Board gender diversity affects the occurrence of environmental violations.

    Ha: Board gender diversity negatively affects the occurrence of environmental violations.

    Hb: Board gender diversity positively affects the occurrence of environmental violations.

    This study employed a sample of non-financial companies listed in the STOXX Europe 600 index over the period 2016–2022. This resulted in an unbalanced panel comprising 3,172 firm-year observations, with 98.03% of firms having five or more observations. Previous literature has widely used the composition of this stock index to analyze the impact of gender diversity on the environmental performance of European firms (Abu Alia et al., 2024; Issa and In'airat, 2024; Giannarakis et al., 2023). The advantages of the STOXX Europe 600 index include its representativeness and amplitude, as it comprises firms from 17 European countries, covering approximately 90% of European market capitalization. In addition, this index includes companies of different sizes and a broad spectrum of sectors as well as firms from different jurisdictions and regulatory systems. The index thus provides a comprehensive view of the European market and allows us to study how boards of directors affect firms' environmental performance. To mitigate the impact of outliers on continuous variables, we apply winsorization at the 1st and 99th percentiles.

    Consistent with previous literature, we collected data on environmental violations and other regulatory actions from the Violation Tracker database belonging to the non-profit organization Good Jobs First (Duan et al., 2024; Foulon & Marsat, 2023; Raghunandan & Rajgopal, 2022; Wu et al., 2021; Wang et al., 2020; Du, 2015). We used the variable to measure environmental violations—VIOL.ENV—defined as the natural logarithm of one plus the number of environmental fines in year t. Penalties are due to firms' violations related to environmental offenses, toxic waste actions, energy conservation violations, maritime violations, nuclear safety, offshore drilling, and zoning violations.

    Environmental fines imposed on firms are a direct and effective proxy for studying environmental misbehavior because they represent an official and sanctioned response to clear violations of environmental laws and regulations, making them verifiable and quantifiable indicators of harmful practices. In addition, they facilitate objective comparison and analysis between different companies and sectors. Moreover, unlike corporate social responsibility (CSR) initiatives, which can be manipulated to improve the image without actual substantial changes in practices, fines reflect real and sanctioned problems, thus avoiding greenwashing.

    Consistent with previous literature, we used two variables widely used in the literature to measure gender diversity. First, the variable WOMEN is defined as the percentage of female directors over the total number of board seats. The number of female directors for the period under study was obtained from each corporate governance report of each company analyzed for each year. Second, we used the variable BLAU, which is a measure of diversity that reflects equity in gender distribution (Blau, 1977). This is widely used in the literature to represent gender diversity (Pucheta‐Martínez & Bel‐Oms, 2019; Al-Shaer & Zaman, 2016; Kılıç & Kuzey, 2016) and varies from 0 (no diversity, all the same gender) to 0.5 (maximum diversity for two genders). The Blau index is calculated with the following formula:

    Blauindex=1ki=1P2i

    where pi is the proportion of each gender in the board.

    The remaining variables include specific characteristics considered in previous research that are expected to determine corporate environmental behaviors. We included firm size (SIZE) since larger firms are more likely to promote bad organizational behaviors (Godfrey et al., 2024; Markoczy et al., 2023). The literature also positively relates unethical behaviors to the use of debt, as a higher level of debt will increase financial risks and thus put pressure on short-term profits while also potentially increasing irresponsibility (Fleitas-Castillo et al., 2024; Kölbel et al., 2017). We therefore incorporated the level of leverage (DEBT) and estimated a positive impact on corporate social irresponsibility (CSI) episodes. We included the return on assets (ROA) variable as a measure of profitability because more profitable firms are less likely to engage in unethical actions (Markoczy et al., 2023; Gao & Yang, 2021). Board size (BOARD) may affect the firm's social conduct, although the relationship may show opposite signs. Larger boards are more likely to represent the interests of multiple stakeholders and have greater resources and capabilities (Zubeltzu-Jaka et al., 2020; Kock et al., 2012). Previous literature has reported inconclusive results regarding how the power of dominant owners impacts firms' social behavior (Bona-Sánchez et al., 2023; Pucheta-Martínez & Chiva-Ortells, 2018; Oh et al., 2017; Barnea & Rubin, 2010). We therefore controlled the power of dominant owners through the variable VOTING. We expected a negative coefficient for growth opportunities (MTB), since the higher the growth opportunities, the lower the need for irresponsible behaviors, with irresponsibility often being linked to scarcity. When more development opportunities are handed, managers tend to make more responsible decisions, since they have the resources to achieve their goals in an ethical and sustainable way (Chen et al., 2022; Gao & Yang, 2021). All variables are defined in Table A1 in the appendix.

    Equation 1 represents the baseline estimation model, where δ represents the sector effect, ϴ the time effect, and ε the error term.

    VIOL.ENVi,t=α+β1WOMENi,t+β2SIZEi,t+β3DEBTi,t+β4ROAi,t+β5BOARDi,t+β6VOTINGi,t+β7MTBi,t+δj+θt+εi,t (1)

    Table 1 shows the distribution of the main sample data (firms, observations, fines, and female directors) distributed for each of the 17 STOXX Europe 600 index countries.

    Table 1.  Data by country.
    Country Number of companies Number of observations Fines (%) Number of women directors (mean) Women directors (%)
    Austria 5 35 5.71 2.40 25.80
    Belgium 9 63 12.70 3.76 30.43
    Denmark 20 140 2.86 2.60 27.64
    Finland 14 98 1.02 2.79 33.63
    France 64 448 10.94 5.26 41.39
    Germany 61 427 17.80 3.98 29.49
    Great Britain 102 709 14.53 3.22 32.74
    Ireland 7 49 24.49 3.16 25.01
    Italy 24 168 6.55 3.61 33.13
    Luxembourg 2 14 42.86 3.76 35.04
    Netherlands 22 136 11.76 2.86 27.56
    Norway 15 105 7.62 2.49 29.51
    Poland 5 35 22.86 0.70 10.06
    Portugal 4 28 0.00 2.89 18.44
    Spain 18 126 2.38 3.49 29.63
    Sweden 48 328 2.13 3.05 32.89
    Switzerland 39 263 10.27 2.06 22.92
    Total 459 3172

     | Show Table
    DownLoad: CSV

    Table 2 shows the descriptive statistics for all the variables. Panel A shows how companies evolved in terms of gender diversity and environmental penalties, with data indicating ever-growing gender diversity. While 94.12% of companies had appointed at least one female director by 2016, this percentage had risen to 98.91% by 2023. In addition, 57.08% of firms had a critical mass of female directors since 2016, rising to 82.14% in 2023. As regards the presence of female directors, women represented an average of 24.88% of board seats in 2016, a percentage that grew to 36.22% in 2023. As for environmental fines, data reflect a reduction in the number of firms committing actions that damage the environment, with the percentage of firms who incurred at least one sanction falling from 15.69% in 2016 to 9.15% in 2023. However, the increase in the year of the COVID-19 pandemic is worthy of note. As regards the number of sanctions for these firms, the average remained constant at around two penalties per firm. Panels B and C provide a summary of the descriptive statistics for the variables used in the estimation models and the correlation matrix of all the variables. Given the low correlation between the primary variables of interest, multicollinearity is unlikely to affect our results, a fact further supported by the low Variance Inflation Factor values (VIF) (Studenmund, 1997).

    Table 2.  Descriptive statistics.
    Panel A. Board gender diversity and environmental penalties
    2016 2017 2018 2019 2020 2021 2022
    Firms with at least one female director (%) 94.12 97.17 98.04 99.35 98.91 99.13 98.91
    Firms with a critical mass of female directors (%) 57.08 62.75 66.45 72.55 76.91 80.83 82.14
    Percentage of female directors 24.88 28.30 29.82 31.93 33.77 35.13 36.22
    Firms with at least one environmental penalty ( & ) 15.69 12.85 12.42 11.76 12.20 9.15 9.15
    Environmental penalties (number) 2.03 1.81 1.65 1.89 1.96 2.07 1.76
    Panel B. Summary statistics
    Mean Median SD 1stQ 3rdQ
    VIOL.ENV 1.12 0 3.59 0 0
    WOMEN 31.55 33.33 11.84 25.00 40.00
    BLAU 0.40 0.44 0.10 0.37 0.48
    MASS3 0.69 1.00 0.46 0.00 1.00
    SIZE 15.86 15.89 1.59 14.84 16.94
    DEBT 3.58 2.33 4.12 0.66 4.93
    ROA 9.13 8.03 7.72 5.04 12.46
    BOARD 2.32 2.30 0.32 2.07 2.48
    VOTING 24.26 16.2 20.57 7.75 35.00
    MTB 0.037 0.035 0.134 0.009 0.014
    Panel C. Correlation matrix
    VIOL.ENV WOMEN SIZE DEBT ROA BOARD VOTING VIF
    WOMEN −0.010 1.04
    SIZE 0.265*** 0.157*** 1.49
    DEBT 0.009 0.034* 0.002 1.01
    ROA −0.074*** −0.033* −0.315*** −0.023 1.13
    BOARD 0.1175*** 0.1061*** 0.534*** 0.024 −0.211*** 1.37
    VOTING −0.068*** 0.037** 0.032* 0.028 0.059*** 0.015 1.02
    MTB −0.046** −0.156*** −0.275*** −0.062*** 0.138*** −0.205*** 0.039* 1.08
    *, **, and *** indicate significance at 10%, 5%, and 1%, respectively.

     | Show Table
    DownLoad: CSV

    We ran an ordinary least squares (OLS) with fixed effects to estimate the relationship between board diversity and environmental violations, which is presented in Models 1–3 of Table 3. Accordingly, and as stated in our hypothesis Ha, the effect of diversity on environmental violations is both negative and significant. This result supports arguments linking board gender diversity to strengthening oversight, improving public perception, access to critical resources, enriching decisions, and promoting a culture of sustainability.

    Table 3.  Board gender diversity and environmental violations.
    Dependent variable VIOL.ENV
    Model 1 Model 2 Model 3
    WOMEN −0.014** (−1.98)
    BLAU −1.738** (−1.97)
    MASS3 −3.312** (−1.74)
    SIZE 0.413*** (3.48) 0.411*** (3.45) 0.541*** (4.73)
    DEBT 0.019 (1.09) 0.020 (1.12) 0.22 (1.34)
    ROA −0.002 (−0.25) −0.002 (−0.22) −0.007 (−0.01)
    BOARD −0.456 (−1.03) −0.410 (−0.92) −0.298 (−0.71)
    VOTING −0.008 (−1.20) −0.008 (−1.23) −0.008 (−1.35)
    MTB −0.685 (−0.61) −0.659 (−0.59) −0.010 (−0.08)
    Model 1 Model 2 Model 3
    Constant −1.003 (−0.39) −0.808 (−0.31) −3.277 (−1.54)
    Soft/hard effect Yes Yes Yes
    Industry effect Yes Yes Yes
    Year effect Yes Yes Yes
    Country effect Yes Yes Yes
    F test 107.51*** 108.7*** 166.14***
    R-squared 0.22 0.22 0.23
    No. of observations 3172 3172 3172
    *, **, and *** indicate significance at 10%, 5%, and 1%, respectively.

     | Show Table
    DownLoad: CSV

    Endogeneity may be a problem because director appointments are not made randomly. Therefore, in Table 4, we used several estimation methods to address this potential problem. In line with Li & He (2023), Yang & Xue (2023), and Mather et al. (2021), we used I.WOMEN, which is defined as the average board diversity of other firms in the same industry and country for each year analyzed. The rationale for using this instrument is that companies within the same industry and country may demonstrate similar behaviors and be influenced by herd psychology when determining their board composition. Furthermore, there are no studies showing that the diversity of other firms in the same sector can directly influence firms' unethical behavior. In addition, the LM and C-D Wald H statistics indicate that the instruments used are relevant and that there is no correlation between the errors and the instrumental variables. To further validate the instrumental variable, we performed a regression of the instruments on environmental violations, which highlights the exclusion criterion. The coefficient of the instrument in this regression is not significant, as shown in Appendix Table A2.

    Table 4.  Board gender diversity and environmental violations.
    Dependent variable VIOL.ENV
    Estimation models TOBIT 2SLS Heckman GMM
    Model 4 Model 5 Model 6 Model 7 Model 8 Model 9 Model 10 Model 11 Model 12 Model 13 Model 14
    WOMEN −0.004*** (−2.77) −0.061*** (−2.34) −0.019** (−2.49) −0.012*** (−12.03)
    BLAU −0.537*** (−2.76) −8.079*** (−2.34) −2.683** (−2.55) −1.781*** (−11.10)
    MASS3 −0.173*** (−2.87) −2.267** (−2.32) −0.257*** (−9.98)
    SIZE 0.055*** (4.88) 0.055*** (4.86) 0.058*** (9.14) 0.006*** (8.59) 0.665*** (8.55) 0.685*** (8.42) 0.653*** (10.87) 0.655*** (10.89) 0.134*** (8.219 0.131*** (7.36) 0.081*** (5.75)
    DEBT 0.0002 (1.63) 0.0002* (1.74) 0.002 (0.84) 0.005 (0.34) 0.006 (0.38) −0.005 (−0.33) 0.001 (0.62) 0.001 (0.63) 0.0009*** (11.83) 0.001*** (15.77) 0.005*** (14.08)
    ROA −0.0005 (0.51) −00005 (−0.57) −0.005 (−0.54) −0.004 (−0.41) −0.284 (−0.84) −0.005 (−0.47) 0.002 (0.72) 0.002 (0.71) −0.013*** (−14.39) −0.014*** (−18.27) −0.011*** (−15.54)
    BOARD −0.041 (−0.82) −0.031 (−0.59) 0.065 (1.38) −0.0420 (−1.29) −0.014*** (−3.60) 1.030 (1.49) −0.331 (−1.10) −0.328 (−1.10) −0.293*** (−7.49) −0.193*** (−4.91) −0.082** (−2.13)
    VOTING −0.001* (−1.67) −0.001* (−1.77) −0.001*** (−3.06) −0.013*** (−3.33) −0.014*** (−3.60) −0.014*** (−3.38) −0.017*** (−4.65) −0.017*** (−4.75) −0.015*** (−6.75) 0.020*** (−8.98) −0.007*** (−4.20)
    MTB −0.043 (−0.35) −0.048 (−0.39) 0.068 (0.95) −0.676 (−0.77) −0.739 (−0.84) 0.989 (1.05) −3.294 (−0.53) −3.511 (−0.57) −2.716*** (−17.81) −2.623*** (−8.98) −2.197*** (−13.17)
    Mill's Lambda −0.523 (−0.59) −0.590 (−0.66)
    Constant −0.040* (−1.81) −0.341 (−1.59) −0.707*** (−5.20) −4.108*** (−2.66) −3.024* (−1.71) −8.098*** (−4.27) −5.384*** (−5.53) −4.927*** (−4.79) 5.684*** (2.51) 3.134*** (2.67) 1.995 (1.63)
    Soft/hard effect Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
    Industry effect Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
    Year effect Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
    Country effect Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
    Wald χ2 646.99*** 94.59*** 638.67*** 343.22*** 343.49***
    Wald test of exogeneity 6.48*** 4.40** 5.72***
    Log-likelihood −8716.92 1927.44 −1477.43
    F test 7.70*** 7.78*** 8.03*** 47.55*** 51.39*** 59.04***
    LM statistic 170.52*** 167.68*** 103.061***
    C–D Wald H test 193.13 183.17 98.01
    M2 0.81 0.80 0.83
    Hansen test 155.19 161.89 150.77
    No. of observations 3172 3172 3172 3172 3172 3172 3172 3172 3172 3172 3172
    *, **, and *** indicate significance at 10%, 5%, and 1%, respectively.

     | Show Table
    DownLoad: CSV

    First, we employed a TOBIT Ⅳ model to account for the fact that many firms do not engage in environmentally damaging practices, which leads to a censored dependent variable. Second, we used the two-stage least squares method (2SLS). Third, we ran Heckman's two-stage correction model to mitigate sample selection bias. In the first stage, we estimated the determinants of gender diversity using a probit model, modeling the probability that a firm is more gender diverse than the industry average as a function of the instrumental variable defined above, and estimating the lambda coefficient or non-selection risk. In the second stage, we used our main regression model and included the lambda coefficient, which describes the covariance between the unobserved factors in the selection equation and the outcome equation. When the Mills coefficient is not significant, it indicates there is no sample selection bias problem. Finally, we used the generalized method of moments (GMM) developed by Blundell & Bond (1998). This technique helps to address potential endogeneity issues arising from the simultaneity between board gender diversity and lack of accountability, as well as from uncontrolled individual heterogeneity. This accounts for problems caused by the absence of unobservable firm characteristics that could affect director appointments. For instance, appointments might be influenced by exogenous characteristics that might also impact firms' environmental violations, potentially leading to a spurious association between board gender diversity and environmental violations.

    The results were consistent across all models, supporting our hypothesis Ha that the presence of female directors on boards is associated with a significant reduction in environmental violations. Female directors contribute to reducing environmental violations by strengthening oversight and control, thereby improving public perception of the firm, providing access to critical resources, enriching decision-making, and adopting a culture of sustainability. Although it is not possible to entirely eliminate all endogeneity problems, the results obtained through the different methods do confirm the main findings and demonstrate that they do not depend on the estimation method applied. As regards the control variables, results indicate that firm size and debt positively affect unethical behavior, while board size, firm profitability, level of ownership concentration, and investment opportunities reduce environmentally harmful behaviors.

    In order to analyze the robustness of the results in Table 5, we divided the sample according to different corporate characteristics. First, Models 15 and 16 show the estimates by dividing the firms according to the size of their market value. Second, Models 17 and 18 separate the firms according to the level of media coverage. We thus considered the number of news items published for each firm through the FACTIVA database, separating firms into two groups: firms with high and low media coverage, depending on whether they have media attention above and below the median number of news items. Finally, in Models 19 and 20, firms are considered according to whether their activity is in regulated sectors (transportation, telecommunications, energy, or construction). The results in all cases are consistent with those obtained previously.

    Table 5.  Board gender diversity and environmental violations.
    Dependent variable VIOL.ENV
    Model 15 Model 16 Model 17 Model 18 Model 19 Model 20
    Larger firms Smaller firms Firms with greater media coverage Firms with less media coverage Firms in regulated industries Firms in non-regulated industries
    WOMEN −0.022*** (−3.96) −0.004*** (−5.08) −0.020*** (−3.32) −0.017*** (−4.37) −0.021*** (−8.32) −0.014*** (−2.83)
    SIZE 0.407*** (3.73) 0.219*** (6.90) 0.603*** (5.23) 0.173** (2.53) 0.636*** (7.85) 0.143** (2.12)
    DEBT 0.032** (2.24) 0.001*** (6.34) 0.003*** (4.98) 0.004 (0.61) 0.010*** (4.89) 0.005 (1.12)
    ROA −0.019** (−2.13) −0.005*** (−6.11) 0.004 (0.10) −0.005 (−1.36) −0.003 (−1.43) −0.005 (−1.01)
    BOARD −1.117** (−2.47) −0.813*** (−6.81) −0.597** (−2.25) −0.0075 (−0.39) −0.415*** (−3.07) −0.257 (−1.01)
    VOTING −0.004 (−0.69) −0.015*** (−4.42) −0.016 (−1.38) −0.001 (−0.46) −0.008*** (−4.18) −0.022*** (−2.66)
    MTB −1.474* (−1.79) −4.059*** (−6.43) 2.897*** (3.24) 1.268** (−2.58) −3.992 (−0.85) 5.347 (0.12)
    Constant −4.813* (−1.85) 2.191* (1.91) −3.495* (−1.72) 0.157 (0.50) −5.988*** (−4.43) 2.455 (1.51)
    Soft/hard effect Yes Yes Yes Yes Yes Yes
    Industry effect Yes Yes Yes Yes Yes Yes
    Year effect Yes Yes Yes Yes Yes Yes
    Country effect Yes Yes Yes Yes Yes Yes
    F test 17.58*** 79.44*** 9.28*** 17.00*** 84.38*** 26.79***
    M2 1.33 −0.26 0.97 −0.84 −0.12 0.88
    Hansen test 71.94 79.14 65.55 51.31 61.64 65.50
    No. of observations 1626 1546 1653 1519 772 2400
    *, **, and *** indicate significance at 10%, 5%, and 1%, respectively.

     | Show Table
    DownLoad: CSV

    Coupled with greater stakeholder concern for corporate actions that impact the environment, the increased presence of women on boards of directors has sharpened academic interest in boosting current knowledge of what effect female directors have on firms' environmental strategies. However, the role of board gender diversity vis-à-vis environmental violations remains a dark area of knowledge. Only the study of Liu (2018), which focused on the context of US firms—where the risk of litigation is high—directly explores the role of female directors in environmental misconduct, with said study showing a negative relationship between gender diversity and environmental violations. Yet this result cannot be directly extrapolated to the continental European setting, which is characterized by low litigation risk, high ownership concentration, and the leading role of reputation as an instrument for disciplining internal stakeholders.

    Accordingly, in this study, we explored what impact the presence of women on boards of directors might have on corporate performance, focusing especially on the environmental misconduct of European firms. Using different theoretical perspectives together with alternative estimation methods and subsamples of firms, our study demonstrates that board gender diversity reduces irresponsible performance that might lead to environmental violations. Consequently, the presence of women on the boards of European firms is shown to be a significant driver in reducing environmental violations. The results provide support for arguments that the presence of female directors can improve control over internal agents by reducing opportunistic and irresponsible behaviors. This role aligns with arguments that point to a greater concern for the reputation of female directors, as they face a narrow labor market. Additionally, results confirm the positive effects of having board members who display greater concern for ethical performance and for addressing stakeholder demands and—in a complementary approach—also suggest that a board composition evidencing a diversity of knowledge, characteristics, and qualities can reduce environmental misconduct. Furthermore, the appointment of female directors aids company legitimacy, as it reduces the risk of engaging in unethical environmental practices and thereby increases the firm's possibilities of long-term sustainability.

    Our research has important implications for policymakers and practitioners alike. By improving our understanding of how and why the inclusion of women on boards can influence firms' environmental performance, we can develop more effective strategies to promote responsible and sustainable corporate governance in the future. The results thus provide support for Directive (EU) 2022/2381, which sets a target of 40% female directors in European listed firms by 2026. As such, findings suggest that establishing gender quotas or other instruments that incentivize the appointment of female directors in other settings may help to reduce unethical environmental performance. For all other stakeholders, the results indicate that firms with a greater presence of female directors are more responsive to the demands of environmentally responsible corporate activity. For managers and controlling owners, the results indicate that the appointment of female directors limits opportunistic practices and signals to all stakeholders the company's commitment to reducing environmental risks related to corporate activity. Consequently, appointing female directors can increase the firm's appeal to a broader set of environmentally conscious investors and consumers and thereby boost the firm's long-term sustainability. In addition, lower environmental risk can reduce the probability of facing stricter regulatory inspections, license suspensions, or restrictions, thus protecting business continuity and stability.

    Nevertheless, our study does evidence certain limitations. Although the use of penalties offers advantages related to objectivity and the use of a quantitative measure of unethical performance, such fines may not fully reflect firms' environmentally responsible actions. Additionally, although we explore the role of female directors as a homogeneous group, it might be enlightening to consider certain characteristics of female directors, such as their seniority in the firm, their ties to controlling shareholders, or their educational background. Future research may therefore seek to shed light on which characteristics of female directors are more closely linked to environmental misconduct. Future inquiry might also explore the role of female directors in environmental strategies in firms that are dominated by families or institutional investors. Furthermore, it would be of interest to investigate this relationship in the Asian setting and in emerging countries in order to bring the board gender diversity–environmental violations relationship out of the dark.

    All authors have contributed equally to the development and writing of this article.

    The authors declare they have not used artificial intelligence (AI) tools in the creation of this article.

    The authors are grateful to anonymous referees for their suggestions and comments on previous versions of the paper. Our thanks go to Professor Ricardo M. Rodrigues of the University of Lisbon for his guidance and advice. This study was supported by the Ministerio de Ciencia e Innovación Project PID2021-124053OB-I00. The research was funded by the University of Las Palmas de Gran Canaria. Any remaining errors are solely the authors' responsibility.

    All the authors declare no conflicts of interest in this paper.


    Abbreviation 5-HT: 5-hydroxytryptamine; CaMKII: Ca-calmodulin dependent protein kinase II; CNS: central nervous system; CPST: Ca-dependent-phorbol esters sensitive,-and a family of serine/threonine protein kinases; CVDs: cardiovascular diseases; DA: dopamine; DMHF: diabetes-mediated heart failure; E: epinephrine; GLUT-4: glucose transporter type-4; HF: heart failure; IL1-β: interleukin 1 beta; IRS-1: Insulin receptor substrate-1; LV: left ventricle; MD: metabolic disorders; NDA: non-diabetic acidosis; NDH: non-diabetic hyperglycemia; NHCl: ammonium chloride; p38 MAPK: p38-mitogen activated protein kinase; PDB: phorbol 12, 13-dibutyrate; PKC-α: protein kinase C-alpha; T1DM: type I diabetes mellitus; TGF-β: transforming growth factor beta; TNF-α: tumor necrosis factor alpha;
    Acknowledgments



    The author(s) are thankful to University of Madras for their financial support in part, during this study.

    Conflict of interest



    There is no potential conflict of interest relevant to this article.

    [1] Ramakrishnan R, Namasivayam A (1995) Norepinephrine and epinephrine levels in the brain of alloxan diabetic rats. Neurosci Lett 186: 200-202. doi: 10.1016/0304-3940(95)11315-N
    [2] Ramakrishnan R, Suthanthirarajan N, Namasivayam A (1996) Brain dopamine in experimental diabetes. Indian J Physiol Pharmacol 40: 193-195.
    [3] Ramakrishnan R, Nazer MY, Suthanthirarajan N, et al. (2003) An experimental analysis of the catecholamine's in hyperglycemia and acidosis induced rat brain. Int J Immunopathol Pharmacol 16: 233-239. doi: 10.1177/039463200301600308
    [4] Ramakrishnan R, Kempuraj D, Prabhakaran K, et al. (2005) A short-term diabetes induced changes of catecholamine's and p38 MAPK in discrete areas of rat brain. Life Sci 77: 1825-1835. doi: 10.1016/j.lfs.2004.12.038
    [5] Ramakrishnan R (2014)  Brain Biogenic Amines in Diabetes LAP Lambert Academic Publishing, 1-148.
    [6] Ramakrishnan R (2019) Brain signaling systems: A target for treating type 1 diabetes mellitus. Brain Res Bull 152: 191-201. doi: 10.1016/j.brainresbull.2019.07.017
    [7] Shpakov AO, Derkach KV, Berstein LM (2015) Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Sci OA 1: FSO25. doi: 10.4155/fso.15.23
    [8] Watson AMD, Gould EAM, Penfold SA, et al. (2019) Diabetes and Hypertension Differentially Affect Renal Catecholamines and Renal Reactive Oxygen Species. Front Physiol 10: 309. doi: 10.3389/fphys.2019.00309
    [9] Akalu Y, Birhan A (2020) Peripheral arterial disease and its associated factors among type 2 diabetes mellitus patients at Debre Tabor general hospital, Northwest Ethiopia. J Diabetes Res 9419413.
    [10] Ramakrishnan R, Sheeladevi R, Suthanthirarajan N (2004) PKC-alpha mediated alterations of indoleamine contents in diabetic rat brain. Brain Res Bull 64: 189-194. doi: 10.1016/j.brainresbull.2004.07.002
    [11] Ramakrishnan R, Prabhakaran K, Jayakumar AR, et al. (2005) Involvement of Ca(2+)/calmodulin-dependent protein kinase II in the modulation of indolamines in diabetic and hyperglycemic rats. J Neurosci Res 80: 518-528. doi: 10.1002/jnr.20499
    [12] Ramakrishnan R, Sheeladevi R, Suthanthirarajan N, et al. (2005) An acute hyperglycemia or acidosis-induced changes of indolamines level correlates with PKC-alpha expression in rat brain. Brain Res Bull 67: 46-52. doi: 10.1016/j.brainresbull.2005.06.001
    [13] Ramakrishnan R, Sheeladevi R, Namasivayam A (2009) Regulation of protein kinases and co-regulatory interplay of S-100β between PKAII and PKC-α on serotonin level in diabetic rat brain. J Neurosci Res 87: 246-259. doi: 10.1002/jnr.21833
    [14] Moran C, Phan TG, Chen J, et al. (2013) Brain Atrophy in Type 2 Diabetes: Regional distribution and influence on cognition. Diabetes Care 36: 4036-4042. doi: 10.2337/dc13-0143
    [15] Moran C, Beare R, Wang W, et al. (2019) Type 2 diabetes mellitus, brain atropy, and cognitive decline. Neurology 92. doi: 10.1212/WNL.0000000000006955
    [16] Chen K (2004) Organization of MAO A and MAO B promoters and regulation of gene expression. Neurotoxicology 25: 31-36. doi: 10.1016/S0161-813X(03)00113-X
    [17] Fang C, Wu B, Le NTT, et al. (2018) Prions activate a p38 MAPK synaptotoxic signaling pathway. PLoS Pathog 14: e1007283. doi: 10.1371/journal.ppat.1007283
    [18] Dewi DAMS, Wiryana M (2019) The interaction of neuroimmunology, neuromodulator, and neurotransmitter with nociceptor and MAPK signaling. J Immunol Res Ther 4: 9.
    [19] Yang X, Guo Z, Lu J, et al. (2017) The Role of MAPK and Dopaminergic Synapse Signaling Pathways in Antidepressant Effect of Electroacupuncture Pretreatment in Chronic Restraint Stress Rats. Evid Based Complement Alternat Med 2357653.
    [20] Elliott G, Juan BG, Jacqueline HF, et al. (2017) Serotonin and catecholamine's in the development and progression of heart valve diseases. Cardiovasc Res 113: 849-857. doi: 10.1093/cvr/cvx092
    [21] Rosano GMC, Vitale C, Seferovic P (2017) Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev 3: 52-55. doi: 10.15420/cfr.2016:20:2
    [22] Packer M (2018) Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care 41: 11-13. doi: 10.2337/dci17-0052
    [23] Kenny HC, Abel ED (2019) Heart Failure in Type 2 Diabetes Mellitus: Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies. Circ Res 124: 121-141. doi: 10.1161/CIRCRESAHA.118.311371
    [24] De Vecchis R, Cantatrione C, Mazzei D, et al. (2016) Non-Ergot-Dopamine Agonists don't Increase the Risk of Heart Failure in Parkinson's disease Patients: A Meta-Analysis of Randomized Controlled Trials. J Clin Med Res 8: 449-460. doi: 10.14740/jocmr2541e
    [25] Evangelista I, Nuti R, Picchioni T, et al. (2019) Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. Int J Mol Sci 20: 3264. doi: 10.3390/ijms20133264
    [26] Tank AW, Lee WD (2015) Peripheral and central effects of circulating catecholamine's. Compr Physiol 5: 1-15.
    [27] Duarte AI, Moreira PI, Oliveira CR (2012) Insulin in central nervous system: more than just a peripheral hormone. J Aging Res 384: 1414-1431.
    [28] Zheng J, Wang Y, Han S, et al. (2018) Identification of Protein Kinase C Isoforms Involved in Type 1 Diabetic Encephalopathy in Mice. J Diabetes Res 8431249.
    [29] Das SK, Yuan YF, Li MQ (2018) Specific PKC βII inhibitor: one stone two birds in the treatment of diabetic foot ulcers. Biosci Rep 38: BSR20171459. doi: 10.1042/BSR20171459
    [30] Nokkaew N, Mongkolpathumrat P, Junsiri R, et al. (2019) p38 MAPK Inhibitor (SB203580) and Metformin Reduces Aortic Protein Carbonyl and Inflammation in Non-obese Type 2 Diabetic Rats. Ind J Clin Biochem 1–7.
    [31] Nokkaew N, Sanit J, Mongkolpathumrat P, et al. (2019) Anti-diabetic drug, metformin, and the p38 inhibitor (SB203580) reduces internal organs oxidative stress in non-obese type 2 diabetic rats. J Appl Pharm Sci 9: 12-20.
    [32] Cramer SC, Sur M, Dobkin BH, et al. (2011) Harnessing neuroplasticity for clinical applications. Brain 134: 1591-1609. doi: 10.1093/brain/awr039
    [33] Hui C, Jingli L, Jiao D, et al. (2015) TAK1 inhibition prevents the development of autoimmune diabetes in NOD mice. Sci Rep 5: 14593. doi: 10.1038/srep14593
    [34] Luchsinger JA, Reitz C, Patel B, et al. (2007) Mayeux, Relation of diabetes to mild cognitive impairment. Arch Neurol 64: 570-575. doi: 10.1001/archneur.64.4.570
    [35] Carvalho C, Cardoso S, Correia SC, et al. (2012) Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes 61: 1234-1242. doi: 10.2337/db11-1186
    [36] Bell DS (2003) Diabetic cardiomyopathy. Diabetes Care 26: 2949-2951. doi: 10.2337/diacare.26.10.2949
    [37] Tschope C, Walther T, Koniger J, et al. (2004) Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. Faseb J 18: 828-835. doi: 10.1096/fj.03-0736com
    [38] Fischer TA, Ludwig S, Flory E, et al. (2001) Activation of cardiac c-Jun NH(2)-terminal kinases and p38-mitogen-activated protein kinases with abrupt changes in hemodynamic load. Hypertension 37: 1222-1228. doi: 10.1161/01.HYP.37.5.1222
    [39] Zhang GX, Kimura S, Nishiyama A, et al. (2004) ROS during the acute phase of Ang-II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension 43: 117-124. doi: 10.1161/01.HYP.0000105110.12667.F8
    [40] Steendijk P, Staal E, Jukema JW, et al. (2001) Hypertonic saline method accurately determines parallel conductance for dual-field conductance catheter. Am J Physiol Heart Circ Physiol 281: H755-H763. doi: 10.1152/ajpheart.2001.281.2.H755
    [41] Steenbergen C (2002) The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol 97: 276-285. doi: 10.1007/s00395-002-0364-9
    [42] Gorog DA, Tanno M, Cao X, et al. (2004) Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia. Cardiovasc Res 61: 123-131. doi: 10.1016/j.cardiores.2003.09.034
    [43] Westermann D, Rutschow S, Van Linthout S, et al. (2006) Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 49: 2507-2513. doi: 10.1007/s00125-006-0385-2
    [44] Pereira S, Yu WQ, Moore J, et al. (2016) Effect of a p38 MAPK inhibitor on FFA-induced hepatic insulin resistance in-vivo. Nutr Diabetes 6: e210. doi: 10.1038/nutd.2016.11
    [45] Xu J, Li J, Hou R, et al. (2019) JPQ downregulates the P38 MAPK signal pathway in skeletal muscle of diabetic rats and increases the insulin sensitivity of Skeletal Muscle. Int J Clin Exp Med 12: 5130-5137.
    [46] Erik V, Marjut L, Hanna F, et al. (2010) Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat. Cardiovasc Diabetol 9: 1-13. doi: 10.1186/1475-2840-9-1
    [47] Wang S, Ding L, Ji H, et al. (2016) The Role of p38 MAPK in the Development of Diabetic Cardiomyopathy. Int J Mol Sci 17: 1037. doi: 10.3390/ijms17071037
    [48] Jantira S, Eakkapote P, Punyanuch A, et al. (2019) Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non-obese type 2 diabetic Goto-Kakizaki rats. Exp Ther Med 18: 1701-1714.
    [49] Xie D, Zhao J, Guo R (2020) Sevoflurane pre-conditioning ameliorates diabetic myocardial ischemia/reperfusion injury via differential regulation of p38 and ERK. Sci Rep 10: 23. doi: 10.1038/s41598-019-56897-8
    [50] Gao F, Yue TL, Shi DW, et al. (2002) p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 53: 414-422. doi: 10.1016/S0008-6363(01)00488-6
    [51] Dubash AD, Kam CY, Aguado BA, et al. (2016) Plakophilin-2 loss promotes TGF-β1/p38 MAPK-dependent fibrotic gene expression in cardiomyocytes. J Cell Biol 212: 425. doi: 10.1083/jcb.201507018
    [52] Umbarkar P, Singh AP, Gupte M, et al. (2019) Cardiomyocyte SMAD4-Dependent TGF-β Signaling is Essential to Maintain Adult Heart Homeostasis. JACC Basic Transl Sci 4: 41-53. doi: 10.1016/j.jacbts.2018.10.003
    [53] Palojoki E, Saraste A, Eriksson A, et al. (2001) Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 280: H2726-H2731. doi: 10.1152/ajpheart.2001.280.6.H2726
    [54] Dong H, Cui B, Hao X (2019) MicroRNA-22 alleviates inflammation in ischemic stroke via p38 MAPK pathways. Mol Med Rep 20: 735-744.
    [55] Yu L, Li Z, Dong X, et al. (2018) Polydatin Protects Diabetic Heart against Ischemia-Reperfusion Injury via Notch1/Hes1-Mediated Activation of Pten/Akt Signaling. Oxid Med Cell Longev 2018: 2750695.
    [56] Stockand JD, Meszaros JG (2003) Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-Ras A and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 284: H176-H184. doi: 10.1152/ajpheart.00421.2002
    [57] Koga Y, Tsurumaki H, Aoki-Saito H, et al. (2019) Roles of Cyclic AMP Response Element Binding Activation in the ERK1/2 and p38 MAPK Signaling Pathway in Central Nervous System, Cardiovascular System, Osteoclast Differentiation and Mucin and Cytokine Production. Int J Mol Sci 20: 1346. doi: 10.3390/ijms20061346
    [58] Turner NA, Blythe NM (2019) Cardiac Fibroblast p38 MAPK: A Critical Regulator of Myocardial Remodeling. J Cardiovasc Dev Dis 6: 27. doi: 10.3390/jcdd6030027
    [59] Thum T, Gross C, Fiedler J, et al. (2008) Micro RNA-21 contributes to myocardial disease by stimulating MAP kinase signaling in fibroblasts. Nature 456: 980-984. doi: 10.1038/nature07511
    [60] Liang Q, Molkentin JD (2003) Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 35: 1385-1394. doi: 10.1016/j.yjmcc.2003.10.001
    [61] Xu Z, Sun J, Tong Q, et al. (2016) The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy. Int J Mol Sci 17: 2001. doi: 10.3390/ijms17122001
    [62] Ruiz M, Coderre L, Allen BG, et al. (2018) Protecting the heart through MK2 modulation, toward a role in diabetic cardiomyopathy and lipid metabolism. Biochim Biophys Acta Mol Basis Dis 1864: 1914-1922. doi: 10.1016/j.bbadis.2017.07.015
    [63] Liao P, Georgakopoulos D, Kovacs A, et al. (2001) The in-vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A 98: 12283-12288. doi: 10.1073/pnas.211086598
    [64] Jia G, Hill MA, Sowers JR (2018) Diabetic Cardiomyopathy An Update of Mechanisms Contributing to This Clinical Entity. Circ Res 122: 624-638. doi: 10.1161/CIRCRESAHA.117.311586
    [65] Streicher JM, Ren S, Herschman H, et al. (2010) MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res 106: 1434-1443. doi: 10.1161/CIRCRESAHA.109.213199
    [66] Hill JA, Olson EN (2008) Cardiac plasticity. N Engl J Med 358: 1370-1380. doi: 10.1056/NEJMra072139
    [67] Vikas K, Kumar A, Rahul S, et al. (2019) Chronic Pressure Overload Results in Deficiency of Mitochondrial Membrane Transporter ABCB7 Which Contributes to Iron Overload, Mitochondrial Dysfunction, Metabolic Shift and Worsens Cardiac Function. Sci Rep 9: 13170. doi: 10.1038/s41598-019-49666-0
    [68] Takeda N, Manabe I, Uchino Y, et al. (2010) Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 120: 254-265. doi: 10.1172/JCI40295
    [69] Small EM (2012) The actin-MRTF-SRF gene regulatory axis and myofibroblast differentiation. J Cardiovasc Transl Res 5: 794-804. doi: 10.1007/s12265-012-9397-0
    [70] Zent J, Guo LW (2018) Signaling Mechanisms of Myofibroblastic Activation: Outside-in and Inside-Out. Cell Physiol Biochem 49: 848-868. doi: 10.1159/000493217
    [71] Bujak M, Frangogiannis NG (2007) The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74: 184-195. doi: 10.1016/j.cardiores.2006.10.002
    [72] Ieda M, Tsuchihashi T, Ivey KN, et al. (2009) Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell 16: 233-244. doi: 10.1016/j.devcel.2008.12.007
    [73] Souders CA, Bowers SL, Baudino TA (2009) Cardiac fibroblast: the renaissance cell. Circ Res 105: 1164-1176. doi: 10.1161/CIRCRESAHA.109.209809
    [74] Kakkar R, Lee RT (2010) Intramyocardial fibroblast myocyte communication. Circ Res 106: 47-57. doi: 10.1161/CIRCRESAHA.109.207456
    [75] Martin ML, Blaxall BC (2012) Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends? J Cardiovasc Transl Res 5: 768-782. doi: 10.1007/s12265-012-9404-5
    [76] Furtado MB, Costa MW, Pranoto EA, et al. (2014) Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ Res 114: 1422-1434. doi: 10.1161/CIRCRESAHA.114.302530
    [77] Miyazaki T, Haraguchi S, Kim-Kaneyama JR, et al. (2019) Endothelial calpain systems orchestrate myofibroblast differentiation during wound healing. FASEB J 33: fj.201800588RR. doi: 10.1096/fj.201800588RR
    [78] Zhang ZY, Wang N, Qian LL, et al. (2020) Glucose fluctuations promote aortic fibrosis through the ROS/p38 MAPK/Runx2 signaling pathway. J Vasc Res 57: 24-33. doi: 10.1159/000503608
    [79] Nian M, Lee P, Khaper N, et al. (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94: 1543-1553. doi: 10.1161/01.RES.0000130526.20854.fa
    [80] Lee MMY, McMurray JJV, Lorenzo-Almorós A, et al. (2016) Diabetic cardiomyopathy. Heart 105.
    [81] Kocabaş U, Yılmaz Ö, Kurtoğlu V (2019) Diabetic cardiomyopathy: acute and reversible left ventricular systolic dysfunction due to cardiotoxicity of hyperglycaemic hyperosmolar state—a case report. Eur Heart J Case Rep 3: ytz049. doi: 10.1093/ehjcr/ytz049
    [82] Gao M, Wang X, Zhang X, et al. (2015) Attenuation of Cardiac Dysfunction in Polymicrobial Sepsis by MicroRNA-146a Is Mediated via Targeting of IRAK1 and TRAF6 Expression. J Immunol 195: 672-682. doi: 10.4049/jimmunol.1403155
    [83] Mann DL (2003) Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 65: 81-101. doi: 10.1146/annurev.physiol.65.092101.142249
    [84] Fiordelisi A, Iaccarino G, Morisco C, et al. (2019) NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases. Int J Mol Sci 20: 1599. doi: 10.3390/ijms20071599
    [85] Frati G, Schirone L, Chimenti I, et al. (2017) An overview of the inflammatory signaling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc Res 113: 378-388. doi: 10.1093/cvr/cvx011
    [86] Sharov VG, Todor A, Suzuki G, et al. (2003) Hypoxia, angiotensin-II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D1. Eur J Heart Fail 5: 121-129. doi: 10.1016/S1388-9842(02)00254-4
    [87] Kaiser RA, Bueno OF, Lips DJ, et al. (2004) Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in-vivo. J Biol Chem 279: 15524-15530. doi: 10.1074/jbc.M313717200
    [88] Wakeman D, Guo J, Santos JA, et al. (2012) p38 MAPK regulates Bax activity and apoptosis in enterocytes at baseline and after intestinal resection. Am J Physiol Gastrointest Liver Physiol 302: G997-1005. doi: 10.1152/ajpgi.00485.2011
    [89] Xu Q, Fang H, Zhao L, et al. (2019) Mechano growth factor attenuates mechanical overload-induced nucleus pulposus cell apoptosis through inhibiting the p38 MAPK pathway. Biosci Rep 39: BSR20182462. doi: 10.1042/BSR20182462
    [90] Aggeli IK, Beis I, Gaitanaki C (2008) Oxidative stress and calpain inhibition induces alpha B-crystallin phosphorylation via p38 MAPK and calcium signaling pathways in H9c2 cells. Cell Signal 20: 1292-1302. doi: 10.1016/j.cellsig.2008.02.019
    [91] Mitra A, Ray A, Datta R, et al. (2014) Cardioprotective role of P38 MAPK during myocardial infarction via parallel activation of alpha-crystallin B and Nrf2. J Cell Physiol 229: 1272-1282. doi: 10.1002/jcp.24565
    [92] Kim JK, Pedram A, Razandi M, et al. (2006) Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. J Biol Chem 281: 6760-6767. doi: 10.1074/jbc.M511024200
    [93] Liu H, Pedram A, Kim JK (2011) Oestrogen prevents cardiomyocyte apoptosis by suppressing p38alpha-mediated activation of p53 and by down-regulating p53 inhibition on p38beta. Cardiovasc Res 89: 119-128. doi: 10.1093/cvr/cvq265
    [94] Wu H, Wang G, Li S, et al. (2015) TNF-α- Mediated-p38-Dependent Signaling Pathway Contributes to Myocyte Apoptosis in Rats Subjected to Surgical Trauma. Cell Physiol Biochem 35: 1454-1466. doi: 10.1159/000373965
    [95] Zuo G, Ren X, Qian X, et al. (2019) Inhibition of JNK and p38 MAPK-mediated inflammation and apoptosis by ivabradine improves cardiac function in streptozotocin-induced diabetic cardiomyopathy. J Cell Physiol 234: 1925-1936. doi: 10.1002/jcp.27070
    [96] Li Z, Ma JY, Kerr I, et al. (2006) Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury. Am J Physiol Heart Circ Physiol 291: H1972-H1977. doi: 10.1152/ajpheart.00043.2006
    [97] Adhikary L, Chow F, Nikolic-Paterson DJ, et al. (2004) Abnormal p38 mitogen-activated protein kinase signaling in human and experimental diabetic nephropathy. Diabetologia 47: 1210-1222. doi: 10.1007/s00125-004-1437-0
    [98] Kojonazarov B, Novoyatleva T, Boehm M, et al. (2017) p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. Am J Respir Cell Mol Biol 57: 603-614. doi: 10.1165/rcmb.2016-0374OC
    [99] Seeger FH, Sedding D, Langheinrich AC, et al. (2010) Inhibition of the p38 MAP kinase in-vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 105: 389-397. doi: 10.1007/s00395-009-0072-9
    [100] Nediani C, Borchi E, Giordano C, et al. (2007) NADPH oxidase-dependent redox signaling in human heart failure: relationship between the left and right ventricle. J Mol Cell Cardiol 42: 826-834. doi: 10.1016/j.yjmcc.2007.01.009
    [101] Newby LK, Marber MS, Melloni C, et al. (2014) SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 384: 1187-1195. doi: 10.1016/S0140-6736(14)60417-7
    [102] Halpern CH, Tekriwal A, Santollo J, et al. (2013) Amelioration of binge eating by nucleus accumbens shell deep brain stimulation in mice involves D2 receptor modulation. J Neurosci 33: 7122-7129. doi: 10.1523/JNEUROSCI.3237-12.2013
    [103] Ter Horst KW, Lammers NM, Trinko R, et al. (2018) Striatal dopamine regulates systemic glucose metabolism in humans and mice. Sci Transl Med 10: eaar3752. doi: 10.1126/scitranslmed.aar3752
    [104] Figee M, De Koning P, Klaassen S, et al. (2014) Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder. Biol Psychiatry 75: 647-652. doi: 10.1016/j.biopsych.2013.06.021
    [105] Boot E, Booij J, Hasler G, et al. (2008) AMPT-induced monoamine depletion in humans: Evaluation of two alternative (123I) IBZM SPECT procedures. Eur J Nucl Med Mol Imaging 35: 1350-1356. doi: 10.1007/s00259-008-0739-8
    [106] Zeng C, Zhang M, Asico LD, et al. (2007) The dopaminergic system in hypertension. Clin Sci 112: 583-597. doi: 10.1042/CS20070018
    [107] Channabasappa S, Sanjay K (2011) Bromocriptine in type 2 diabetes mellitus. Indian J Endocrinol Metab 15: S17-S24. doi: 10.4103/2230-8210.83058
    [108] Reda E, Hassaneen S, El-Abhar HS (2018) Novel Trajectories of Bromocriptine Antidiabetic Action: Leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/Adiponectin, Nrf2/PARP-1, and GLP-1. Front Pharmacol 9: 771. doi: 10.3389/fphar.2018.00771
    [109] Leicht M, Briest W, Zimmer HG (2003) Regulation of norepinephrine-induced proliferation in cardiac fibroblasts by interleukin-6 and p42/p44 mitogen activated protein kinase. Mol Cell Biochem 243: 65-72. doi: 10.1023/A:1021655023870
    [110] Lubahn CL, Lorton D, Schaller JA, et al. (2014) Targeting a-and b-adrenergic receptors differentially shift Th1, Th2, and inflammatory cytokine profiles in immune organs to attenuate adjuvant arthritis. Front Immunol 5: 346. doi: 10.3389/fimmu.2014.00346
    [111] Moliner P, Enjuanes C, Tajes M, et al. (2019) Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron Deficiency More Than a Comorbidity? J Am Heart Assoc 8: e010887. doi: 10.1161/JAHA.118.010887
    [112] Zhang P, Li Y, Nie K, et al. (2018) Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review. BMC Neurol 18: 221. doi: 10.1186/s12883-018-1230-1
    [113] Michael E, Shuqin L, Nicholas C, et al. (2019) 1793-P: Dopamine D1 plus D2 Receptor Coactivation Ameliorates Metabolic Syndrome (MS) and Nonalcoholic Fatty Liver Disease (NAFLD) in Mice. Diabetes 68.
    [114] Monti JM, Monti D (2007) The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 11: 113-133. doi: 10.1016/j.smrv.2006.08.003
    [115] Wang X, Wang ZB, Luo C, et al. (2019) The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor. J Cancer 10: 1622-1632. doi: 10.7150/jca.27780
    [116] Chávez-Castillo M, Ortega Á, Nava M, et al. (2018) Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable? Vessel Plus 2: 6. doi: 10.20517/2574-1209.2018.02
    [117] Fortier JH, Pizzarotti B, Shaw RE, et al. (2019) Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis. Heart 105: 1140-1148.
    [118] Mawe GM, Hoffman JM (2013) Serotonin signaling in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 10: 473-486. doi: 10.1038/nrgastro.2013.105
    [119] Selim AM, Sarswat N, Kelesidis I, et al. (2017) Plasma Serotonin in Heart Failure: Possible Marker and Potential Treatment Target. Heart Lung Circ 26: 442-449. doi: 10.1016/j.hlc.2016.08.003
    [120] Guo S, Chen L, Cheng S, et al. (2019) Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials. Medicine 98: e15786. doi: 10.1097/MD.0000000000015786
    [121] Lancellotti P, Nchimi A, Hego A, et al. (2015) High-dose oral intake of serotonin induces valvular heart disease in rabbits. Int J Cardiol 197: 72-75. doi: 10.1016/j.ijcard.2015.06.035
    [122] Seferovic PM, Ponikowski P, Anker SD, et al. (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21: 1169-1186. doi: 10.1002/ejhf.1531
    [123] Shimizu Y, Minatoguchi S, Hashimoto K, et al. (2002) The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J Am Coll Cardiol 40: 1347-1355. doi: 10.1016/S0735-1097(02)02158-7
    [124] Chen YG, Mathews CE, Driver JP (2018) The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future. Front Endocrinol 9: 51. doi: 10.3389/fendo.2018.00051
    [125] Pei Y, Cui F, Du X, et al. (2019) Antioxidative nanofullerol inhibits macrophage activation and development of osteoarthritis in rats. Int J Nanomedicine 14: 4145-4155. doi: 10.2147/IJN.S202466
    [126] Kullmann S, Heni M, Hallschmid M, et al. (2016) Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans. Physiol Rev 96: 169-209. doi: 10.1152/physrev.00032.2015
    [127] Grillo CA, Woodruff JL, Macht VA, et al. (2019) Insulin resistance and hippocampal dysfunction: Disentangling peripheral and brain causes from consequences. Exp Neurol 318: 71-77. doi: 10.1016/j.expneurol.2019.04.012
    [128] Nakabeppu Y (2019) Origins of brain insulin and its function. In: Diabetes Mellitus. Advances in Experimental Medicine and Biology. Adv Exp Med Biol 1128: 1-11. doi: 10.1007/978-981-13-3540-2_1
    [129] Bode BW, Garg SK (2016) The Emerging Role of Adjunctive Noninsulin Anti-hyperglycemic Therapy in the Management of Type 1 Diabetes. Endocr Pract 22: 220-230. doi: 10.4158/EP15869.RA
    [130] Otto-Buczkowska E, Nowowiejska B, Jarosz-Chobot P, et al. (2009) Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents? Przegl Lek 66: 388-393.
    [131] Otto-Buczkowska E, Natalia J (2018) Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else? Int J Endocrinol Metab 16: e13008.
    [132] Grizzanti J, Corrigan R, Casadesusa G (2018) Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition. J Alzheimers Dis 66: 11-23. doi: 10.3233/JAD-180433
    [133] Alicic RZ, Neumiller JJ, Johnson EJ, et al. (2019) Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes 68: 248-257. doi: 10.2337/dbi18-0007
    [134] Mullane K, Williams M (2019) Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity. Curr Protoc Pharmacol 84: e57. doi: 10.1002/cpph.57
    [135] Antal Z, Baker JC, Smith C, et al. (2012) Beyond HLA-A*0201: new HLA-transgenic non-obese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+T cell epitopes. J Immunol 188: 5766-5775. doi: 10.4049/jimmunol.1102930
    [136] Serr P, Santamaria P (2019) Antigen-specific therapeutic approaches for autoimmunity. Nature Biotechnol 37: 238-251. doi: 10.1038/s41587-019-0015-4
    [137] Singer-Englar T, Barlow G, Mathur R (2018) Obesity, diabetes, and the gut microbiome: an updated review. Expert Rev Gastroenterol Hepatol 13: 3-15. doi: 10.1080/17474124.2019.1543023
    [138] Siljandera H, Honkanenb J, Knipa M (2019) Microbiome and type 1 diabetes. Ebiomedicine 46: 512-521. doi: 10.1016/j.ebiom.2019.06.031
    [139] Escós A, Risco A, Alsina-Beauchamp D, et al. (2016) p38γ and p38δ Mitogen Activated Protein Kinases (MAPKs), New Stars in the MAPK Galaxy. Front Cell Dev Biol 4: 31. doi: 10.3389/fcell.2016.00031
    [140] Cuenda A, Rousseau S (2007) p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375. doi: 10.1016/j.bbamcr.2007.03.010
    [141] Beardmore VA, Hinton HJ, Eftychi C, et al. (2005) Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 25: 10454-10464. doi: 10.1128/MCB.25.23.10454-10464.2005
    [142] Remy G, Risco AM, Iñesta-Vaquera FA, et al. (2010) Differential activation of p38 MAPK isoforms by MKK6 and MKK3. Cell Signal 22: 660-667. doi: 10.1016/j.cellsig.2009.11.020
    [143] Jiang Y, Gram H, Zhao M, et al. (1997) Characterization of the structure and function of the fourth member of p38 group mitogen activated protein kinases, p38δJ Biol Chem 272: 30122-30128. doi: 10.1074/jbc.272.48.30122
    [144] Sumara G, Formentini I, Collinsetal S (2009) Regulation of PKD by the MAPK p38 delta in insulin secretion and glucose homeostasis. Cell 136: 235-248. doi: 10.1016/j.cell.2008.11.018
    [145] Lee JC, Laydon JT, McDonnelletal PC (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746. doi: 10.1038/372739a0
    [146] Jiang Y, Chen C, Li Z, et al. (1996) Characterization of the structure and function of a new mitogen activated protein kinase (p38β). J Biol Chem 271: 17920-17926. doi: 10.1074/jbc.271.30.17920
    [147] Cuenda A, Rouse J, Dozaetal YN (1995) SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Letters 364: 229-233. doi: 10.1016/0014-5793(95)00357-F
    [148] Ramachandra CJ, Mehta A, Wong P, et al. (2016) ErbB4 Activated p38gamma MAPK isoform mediates early cardiogenesis through NKx2.5 in human pluripotent stem cells. Stem Cells 34: 288-298. doi: 10.1002/stem.2223
    [149] González-Terán B, López JA, Rodríguez E, et al. (2016) p38gamma and delta promote heart hypertrophy by targeting the mTOR-inhibitory protein DEPTOR for degradation. Nat Commun 7: 10477. doi: 10.1038/ncomms10477
    [150] Cuevas BD, Abell AN, Johnson GL (2007) Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 26: 3159-3171. doi: 10.1038/sj.onc.1210409
    [151] Cuenda A, Rousseau S (2007) p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375. doi: 10.1016/j.bbamcr.2007.03.010
    [152] Chang CI, Xu BE, Akella R, et al. (2002) Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol Cell 9: 1241-1249. doi: 10.1016/S1097-2765(02)00525-7
    [153] Biondi RM, Nebreda AR (2003) Signaling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J 372: 1-13. doi: 10.1042/bj20021641
    [154] Enslen H, Brancho DM, Davis RJ (2000) Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. EMBO J 19: 1301-1311. doi: 10.1093/emboj/19.6.1301
    [155] Tomlinson DR (1999) Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 42: 1271-1281. doi: 10.1007/s001250051439
    [156] Begum N, Ragolia L (2000) High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol Cell Physiol 278: C81-C91. doi: 10.1152/ajpcell.2000.278.1.C81
    [157] Chen S, Qiong Y, Gardner DG (2006) Aroleforp38mitogen-activatedproteinkinase and c-Myc inendothelin-dependent rat aortic smooth muscle cell proliferation. Hypertension 47: 252-258. doi: 10.1161/01.HYP.0000198424.93598.6b
    [158] Natarajan R, Scott S, Bai W, et al. (1999) Angiotensin II signaling in vascular smoothmuscle cells under high glucose conditions. Hypertension 33: 378-384. doi: 10.1161/01.HYP.33.1.378
    [159] Igarashi M, Wakasaki H, Takahara N, et al. (1999) Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 103: 185-195. doi: 10.1172/JCI3326
    [160] Dorenkamp M, Riad AS, Stiehl S, et al. (2005) Protection against oxidative stress indiabetic rats: role of angiotensinAT1 receptor and beta 1-adrenoceptor antagonism. Eur J Pharmacol 520: 179-187. doi: 10.1016/j.ejphar.2005.07.020
    [161] Begum N, Ragolia L (2000) High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol Cell Physiol 278: C81-C91. doi: 10.1152/ajpcell.2000.278.1.C81
    [162] Chen S, Qiong Y, Gardner DG (2006) A role for p38 mitogen-activated protein kinase and c-Myc in endothelin-dependent rat aortic smooth muscle cell proliferation. Hypertension 47: 252-258. doi: 10.1161/01.HYP.0000198424.93598.6b
    [163] Cain BS, Meldrum DR, Meng X, et al. (1999) p38 MAPK inhibition decreases TNF-α production and enhances post ischemic human myocardial function. J Surg Res 83: 7-12. doi: 10.1006/jsre.1998.5548
    [164] Communal C, Colucci WS, Singh K (2000) p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes againstβ-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation. J Biol Chem 275: 19395-19400. doi: 10.1074/jbc.M910471199
    [165] Liang Q, Molkentin JD (2003) Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 35: 1385-1394. doi: 10.1016/j.yjmcc.2003.10.001
    [166] Li M, Georgakopoulos D, Luetal G (2005) p38MAPkinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 111: 2494-2502. doi: 10.1161/01.CIR.0000165117.71483.0C
    [167] Hu SS, Kong LZ, Gaoetal RL (2010) Outline of the report on cardiovascular disease in China. Biomed Environ Sci 25: 251-256.
    [168] Yang HS, Zheng QY, Duetal YY (2016) Influence of different acupoint combinations on immediate effect of surface electromyography of patients with cervical spondylosis. World J Acupunct Moxibustion 26: 7-13. doi: 10.1016/S1003-5257(17)30056-9
    [169] Pan YX, Chen KF, Lin YX, et al. (2013) Intracisternal administration of SB203580, a p38 mitogen-activated protein kinase tumor necrosis factor-alpha. J Clin Neurosci 20: 726-730. doi: 10.1016/j.jocn.2012.09.012
    [170] Wu S, Li J, Hong YQ, et al. (2012) Efects of electroacupuncture at Neiguan (PC 6) on p38 MAPK signaling pathway in rats with cardiac hypertrophy. Chin Acupunct Moxibustion 32: 145-148.
    [171] Du Y, Tang J, Li G, et al. (2010) Effects of p38 MAPK Inhibition on Early Stages of Diabetic Retinopathy and Sensory Nerve Function. Invest Ophthalmol Vis Sci 51: 2158-2164. doi: 10.1167/iovs.09-3674
    [172] Wang S, Ding L, Zheng Y, et al. (2016) The role of p38 MAPK in the development of diabetic cardiomyopathy. Int J Mol Sci 17: 1037. doi: 10.3390/ijms17071037
    [173] Muslin AJ (2008) MAPK signaling in cardiovascular health and disease: Molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115: 203-218. doi: 10.1042/CS20070430
    [174] Radi ZA, Marusak RA, Morris DL (2009) Species comparison of the role of p38 MAPK in the female reproductive system. J Toxicol Pathol 22: 109-124. doi: 10.1293/tox.22.109
  • Reader Comments
  • © 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5849) PDF downloads(97) Cited by(3)

Figures and Tables

Figures(3)  /  Tables(1)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog